ViiV Wins Fast-Track Review At EMA For HIV Therapy
A number of new products have been submitted for review at the European Medicines Agency. While marketing authorization applications from ViiV Healthcare and BioMarin Pharmaceutical are being fast-tracked, a submission from Incyte is not.
You may also be interested in...
The European Medicines Agency has agreed to review pan-EU marketing applications for a number of new medicines.
Hot on the heels of winning EU fast-track review status for belantamab mafodotin, GlaxoSmithKline has asked the European Medicines Agency to grant accelerated assessment to another of its planned marketing applications.
New medicines under evaluation at the European Medicines Agency.